OraSure Technologies Downgraded by Zacks to Neutral (OSUR)
OraSure Technologies (NASDAQ:OSUR) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued to clients and investors on Tuesday. They currently have a $9.20 price objective on the stock. Zacks‘s price target points to a potential upside of 19.17% from the stock’s previous close.
Shares of OraSure Technologies (NASDAQ:OSUR) traded down 1.63% during mid-day trading on Tuesday, hitting $7.5945. 323,624 shares of the company’s stock traded hands. OraSure Technologies has a 1-year low of $4.67 and a 1-year high of $9.00. The stock’s 50-day moving average is $8.31 and its 200-day moving average is $7.2. The company has a market cap of $425.2 million and a P/E ratio of 406.32.
OraSure Technologies (NASDAQ:OSUR) last announced its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.04) by $0.08. The company had revenue of $26.40 million for the quarter, compared to the consensus estimate of $26.21 million. During the same quarter last year, the company posted ($0.10) earnings per share. OraSure Technologies’s revenue was up 8.5% compared to the same quarter last year. On average, analysts predict that OraSure Technologies will post $-0.15 earnings per share for the current fiscal year.
Several other analysts have also recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of OraSure Technologies in a research note on Thursday, June 12th. They now have a $10.00 price target on the stock, up previously from $9.00. Separately, analysts at Raymond James raised their price target on shares of OraSure Technologies from $8.50 to $9.00 in a research note on Thursday, June 12th. Finally, analysts at Canaccord Genuity raised their price target on shares of OraSure Technologies from $10.00 to $11.00 in a research note on Thursday, June 12th. They now have a “buy” rating on the stock. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $9.70.
OraSure Technologies, Inc, is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using the Company’s oral fluid technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
To view Zacks’ full report, visit Zacks’ official website.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.